<?xml version="1.0" encoding="UTF-8"?>
<collection>
<dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:invenio="http://invenio-software.org/elements/1.0" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd"><dc:identifier>doi:10.1016/j.vaccine.2013.07.051</dc:identifier><dc:language>eng</dc:language><dc:creator>Arbues, Ainhoa</dc:creator><dc:creator>Aguilo, Juan I.</dc:creator><dc:creator>Gonzalo-Asensio, Jesús</dc:creator><dc:creator>Marinova, Dessislava</dc:creator><dc:creator>Uranga, Santiago</dc:creator><dc:creator>Puentes, Eugenia</dc:creator><dc:creator>Fernández, Conchita</dc:creator><dc:creator>Parra, Alberto</dc:creator><dc:creator>Cardona, Pere Joan</dc:creator><dc:creator>Vilaplana, Cristina</dc:creator><dc:creator>Ausina, Vicente</dc:creator><dc:creator>Williams, Ann</dc:creator><dc:creator>Clark, Simon</dc:creator><dc:creator>Malaga, Wladimir</dc:creator><dc:creator>Guilhot, Christophe</dc:creator><dc:creator>Gicquel, Brigitte</dc:creator><dc:creator>Martin, Carlos</dc:creator><dc:title>Construction, characterization and preclinical evaluation of MTBVAC, the first live-attenuated M. tuberculosis-based vaccine to enter clinical trials</dc:title><dc:identifier>ART-2013-85742</dc:identifier><dc:description>The development of a new tuberculosis vaccine is an urgent need due to the failure of the current vaccine, BCG, to protect against the respiratory form of the disease. MTBVAC is an attenuated Mycobacterium tuberculosis vaccine candidate genetically engineered to fulfil the Geneva consensus requirements to enter human clinical trials. We selected a M. tuberculosis clinical isolate to generate two independent deletions without antibiotic-resistance markers in the genes phoP, coding for a transcription factor key for the regulation of M. tuberculosis virulence, and fadD26, essential for the synthesis of the complex lipids phthiocerol dimycocerosates (DIM), one ofthe major mycobacterial virulence factors. The resultant strain MTBVAC exhibits safety and biodistribution profiles similar to BCG and confers superior protection in preclinical studies. These features have enabled MTBVAC to be the first live attenuated M. tuberculosis vaccine to enter clinical evaluation.</dc:description><dc:date>2013</dc:date><dc:source>http://zaguan.unizar.es/record/61676</dc:source><dc:doi>10.1016/j.vaccine.2013.07.051</dc:doi><dc:identifier>http://zaguan.unizar.es/record/61676</dc:identifier><dc:identifier>oai:zaguan.unizar.es:61676</dc:identifier><dc:relation>info:eu-repo/grantAgreement/EC/FP7/241745/EU/Discovery and preclinical development of new generation tuberculosis vaccines/NEWTBVAC</dc:relation><dc:relation>info:eu-repo/grantAgreement/ES/MICINN/Juan de la Cierva Program-JCI-2009-03799</dc:relation><dc:relation>info:eu-repo/grantAgreement/ES/MINECO/BES-2006-11950</dc:relation><dc:relation>info:eu-repo/grantAgreement/ES/MINECO/BIO2008-01561</dc:relation><dc:relation>info:eu-repo/grantAgreement/ES/MINECO/BIO2011-23555</dc:relation><dc:identifier.citation>VACCINE 31, 42 (2013), 4867-4873</dc:identifier.citation><dc:rights>by-nc-nd</dc:rights><dc:rights>http://creativecommons.org/licenses/by-nc-nd/3.0/es/</dc:rights><dc:rights>info:eu-repo/semantics/openAccess</dc:rights></dc:dc>

</collection>